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ABSTRACT 
Head and neck cancer (HNC) accounts for 3-5% of all malignancies in the 
United States and is the sixth most common cancer worldwide.  Over the past two 
decades, radiation therapy (RT) has become a frequent therapeutic strategy, however 
one of its side effects, dysphagia has had a huge impact on patients’ quality of life. 
The value of determining the true prevalence of dysphagia is remarkable, which is 
what prompted us to carry out a study to determine the prevalence, trends, and risk 
factors for dysphagia following completion of RT over one year in patients diagnosed 
with HNC at Boston Medical Center over a 7-year period. 
A retrospective cohort study was conducted that involved a chart review of the 
medical records of all patients who completed RT for HNC cancer from January 1, 
2003 to December 31, 2009 at Boston University Medical Center.  113 eligible 
patients were who had comprehensive treatment and follow up data at 3, 6, 9 or 12 
 
 months post RT were analyzed.  Outcome variables of interest included feeding tube 
status, diet status, subjective swallow status, and percent weight loss from end of RT.  
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113 patients were identified for this study, of which 31% (n=35) were female 
and 69% (n=78) were male.  Average age was 58.6 years old (35 to 88).  The most 
common cancer sites were oropharynx and nasopharynx (38.9%) as well as 
hypopharynx and larynx (31%). 71.7% of the cohort had chemotherapy (CT) in 
addition to RT, and about half the patients had some degree of surgery. Altogether, 
the most “clinically meaningful” indicator of dysphagia (diet level of moderate/severe 
diet restriction) showed that the prevalence or probability of dysphagia to be 49% at 3 
months, 56% at 6 months, 45% at 9 months, and 31% at 12 months.   
Our results suggest that about half the patients who undergo RT may be 
expected to develop a significant swallowing dysfunction in the first year following 
RT.  This is extremely useful data for a health care provider to present to a patient 
after diagnosis of HNC and should complement counseling provided to them at the 
time of creating a treatment plan.  Interestingly most of the patients who developed 
moderate/severe dysphagia did so within the first 6 months of completion of RT.  
Only oral cavity as cancer site was associated with moderate/severe dysphagia in our 
cohort of patients.   
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INTRODUCTION 
 
Background 
Head and neck cancer (HNC) refers to an array of malignant tumors that originate in 
the oral cavity, larynx, pharynx, nasal cavity, paranasal sinuses, and salivary glands. 
Over 80% of HNCs are squamous cell carcinomas, with adenocarcinomas, 
mucoepidermoid carcinomas, and adenoid cystic carcinomas making up the remaining 
histological types (1).  HNC accounts for three to five percent of all malignancies in 
the United States (2), it is the sixth most common cancer worldwide (3), and was 
reported to be the eighth leading cause of cancer deaths in 2000 (4).  The estimated 
number of new HNC cases in 2010 was 49,260 (35,530 in men and 13,730 in women) 
(5), and the estimated prevalence in 2007 was 339,000 cases (6).  Primary risk factors 
for HNC development are tobacco and alcohol, especially when used concomitantly, 
and the human papilloma virus (HPV) (4, 5). 
 
Over the past two decades, the use of Radiation Therapy (RT) has become a more 
prevalent therapeutic strategy.  The increased use of chemotherapy + radiation therapy 
(CRT) is often attributed to the VA Laryngeal Cancer Study Group, which in 1991, 
concluded that there was no difference in 2 year survival rates between patients with 
advanced stage laryngeal cancer who received CRT vs. patients who received surgery 
and RT (7).  Organ preservation, through surgery avoidance was then assumed to be 
the preferable treatment if outcomes were the same.  In patients who undergo surgical 
resection for HNC, the cause of dysphagia is evident.  Unfortunately, RT and/or CRT 
sometimes fail to preserve the functional integrity of the organ, which can lead to 
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compromised ability to eat and/or drink, and subsequently may adversely impact 
quality of life (QOL).  
 
Long-term morbidities associated with RT or CRT (which, from this point on, will 
collectively be referred to as “RT”) include dry mouth (xerostomia), altered taste, 
reduced sensory input, and swallowing impairment (dysphagia) (8) (see Table 1).  
Among these, dysphagia is often considered the most adverse complication.  
Knowledge of the specific molecular and biomechanical causes of RT-induced 
dysphagia remains limited.  What has been recognized is that RT produces an acute 
and repeated inflammatory response, with substantial vascular damage and tissue 
remodeling in the area of soft tissue and mucosa exposed to RT (9).  
 
Table 1: Radiation therapy-induced swallowing abnormalities8 
 
Oral phase abnormalities 
• Reduced sensory input 
• Loss of muscles in the cheek 
• Drooling 
• Impaired  oral opening 
• Limitations on food bolus positioning 
• Delayed initiation of swallowing 
 
Pharyngeal phase abnormalities 
• Impaired transport of food through pharynx 
• Impairs clearance from pharynx 
• Increased risk of aspiration 
• Reduced epiglottis motion 
• Reduced pharyngeal constrictors’ contraction 
• Reduced cricopharyngeal opening, resulting in increased pharyngeal residue 
 
 
 
Health care providers including physicians, nurses, and therapists involved in the care 
of a patient with HNC should be familiar with the essentials of normal swallowing 
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function, the mechanism of RT-induced dysphagia, trends of dysphagia following 
completion of RT, and measures that may help to prevent and treat dysphagia.  
 
 
Radiation Therapy (RT) 
RT is frequently used as a therapeutic option in cancer treatment. Radiation is energy 
carried by a stream of particles or waves.  The therapeutic agent in RT is ionizing 
radiation, which is divided into two groups; the corpuscular group and the 
electromagnetic group, also called photons (10).  Protons, electrons, and neutrons 
represent corpuscular radiation, whereas X-rays and gamma rays represent 
electromagnetic radiation, the latter group being the most common form of RT in 
clinical practice (10).  The unit used to express amount of absorbed radiation by 
tissues is the Gray (Gy), an international unit (SI unit), defined as 1 joule per kilogram 
(kg).  The Gray replaced the traditional rad (radiation absorbed dose) unit in 1975, 
although the rad is often persistently used in the U.S. where 1 Gy is equal to 100 rad 
(10, 11, 12).  RT regimens are administered on average over five to seven weeks with 
a total curative dose of 50-70 Gy.  Pre-operative dosages are usually 45 Gy and post-
operative dosages are 55-60 Gy.  
 
Radiation targets and damages the deoxyribonucleic acid (DNA) in cancer cells, 
impairing their division and growth.  To better comprehend the mechanism by which 
radiation works, it is important to understand the normal life cycle of a cell.  The cell 
cycle runs through five phases; G0 (resting cell), G1 (cell starts to make proteins and 
material for DNA), S (chromosomes with DNA are duplicated), G2 (just before the 
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cell splits into two cells), and M (mitosis, when the cell divides into two identical 
cells).  Radiation first kills cells that are actively or rapidly dividing while in the M 
phase of division.  Malignant cells, which have a tendency to divide rapidly and grow 
out of control, are therefore preferentially killed by RT.  Although RT kills malignant 
cells, it also affects dividing cells in normal tissues, which can result in undesired side 
effects.  Rapid-growing tissues include skin, bone marrow, and intestinal lining, 
which may be affected immediately following RT.  As a result, radiation oncologists 
always consider the fine balance between maximizing destruction of malignant cells 
and minimizing damage to normal cells.  
 
Relative susceptibility to the effects of radiation varies by type of cancer cell, and is 
referred to as radiosensitivity (10).  RT may be direct or indirect, depending on the 
wavelength of the incident photon.  If administered directly, the DNA molecule is 
cleaved, thwarting duplication.  During indirect administration, water is dissociated 
into its ionic state (H+ and OH-), permitting OH-, a reactive oxygen species (ROS) to 
react with DNA and interfering with its duplication (10).  This is termed ionizing 
radiation.  Interestingly most of a cell’s content is water, and hence the effects of 
indirect (ionizing) RT are more significant compared to those of direct RT (13).   
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Normal Swallowing Function 
Swallowing is an intricate process that involves multiple muscles in the oral cavity, 
esophagus, pharynx, and larynx.  It is initiated by sensory stimuli that are transmitted 
to the brainstem and cortex where the presence of a bolus is recognized and a motor 
signal is sent to the peripheral muscles.  The “swallowing center” lies within the 
brainstem but substantial supratentorial involvement is usually involved in the 
deglutition process.  Normal swallowing is usually divided into three phases (14).  
Phase 1 (oral preparatory phase) consists of breakdown of food by chewing and 
salivary lubrication to form a bolus.  Phase 2 (oral phase) transports the bolus from the 
anterior tongue back towards the oropharynx.  Finally, Phase 3 (pharyngeal phase) 
results in the initiation of the swallow and propulsion of the bolus towards the cervical 
esophagus as the larynx closes to protect the airway (14).  A disruption in the 
swallowing process is known as dysphagia. 
 
Dysphagia can result in compromised nutritional status, depression, anxiety, 
aspiration pneumonia, and hence a compromised quality of life (15-18).  Since 
dysphagia has such a profound affect on a patient’s health and QoL, radiation 
oncologists have tried to employ radio protectors to mitigate dysphagia in head and 
neck cancer patients undergoing RT.  Unfortunately such techniques have not been 
successful in reducing permanent dysphagia (19). 
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Dysphagia Induced by Radiation 
Surgical resection and transection of muscles and nerves can result in tissue and 
structural loss, scar tissue formation, and loss of sensation, all of which can alter 
normal swallowing in a predictable manner.  RT however, may cause a short- or long-
term dysphagia of varying severities, and the etiology of the problem as well as the 
underlying mechanisms that drive the pathophysiology are poorly understood.  One 
preliminary study identified the pharyngeal constrictor muscles and the larynx as the 
“crucial” structures associated with an increased risk of swallowing dysfunction based 
on videofluoroscopic evaluations following administration of Intensity Modulated 
Radiation Therapy (IMRT), which spared different muscle groups (20).  However an 
alternative study suggested that the suprahyoid muscles are just as significant (21). 
 
After completion of RT, the normal controlled healing process should continue until a 
patient is fully recovered (about 3 months post RT).  However, some patients continue 
to react to the insult with an abnormal uncontrolled healing process.  In these latter 
patients, an aberrant fibrotic response develops and continues for an undetermined 
period of time.  Fibrosis has been described as a progressive problem related to an 
impaired wound healing process (22).  Fibrosis and associated stiffness of tissues has 
been identified as the primary cause of dysphagia (8). 
 
Damage to soft tissue and mucosa can begin within a few days of initiation of RT 
within the radiation field (23).  This damage, along with a vigorous inflammatory 
reaction causes the acute effects of RT (during RT and up to 3mo post RT) (24). 
These acute effects can include pain, thickened, viscous mucous production, dry 
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mouth, erythema, and tissue swelling.  Additionally, mucositis can be caused by 
environmental factors such as colonization of oral microflora (23). 
 
Hypoxia caused by vascular damage and chronic oxidative stress during the course of 
RT may promote the fibrotic process and propagate further tissue injury after RT 
completion (25).  This may partially explain why some patients develop dysphagia 
years after completion of RT.  Long-term effect of RT-induced injury to neural 
structures has also been suggested as contributing to long term (greater than 3mo post 
RT) impairment of swallowing function (8).  The variations in RT-related toxicities 
may in part be related to genetic predisposition (23). 
  
 
Prevention and Treatment of Dysphagia 
The mean dose and volume of intensity modulated radiation therapy (IMRT) to the 
pharyngeal constrictor muscles and larynx have been shown to highly correlate with 
the development of long term dysphagia (20, 26, 27).  The implication is that sparing 
of the pharyngeal constrictor muscles and laryngeal structures from a significant 
radiation dose (50Gy or more) may prevent development of dysphagia in certain 
cases.  However, specific dose or volume restrictions have not been established so 
optimal treatment entails minimizing the mean dose whenever possible (28).  
 
Few prospective cohort studies or randomized trials evaluating therapeutic or 
preventive measures for dysphagia have been conducted in patients with HNC. 
Therapeutic options include a Food and Drug Administration (FDA) approved drug 
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called amifostine, a free radical scavenger that may be added to treatment regimens to 
minimize side effects.  Randomized controlled trials have demonstrated its efficacy in 
prevention of xerostomia secondary to RT (29).  A meta-analysis evaluating the 
efficacy and toxicity of amifostine also showed that the rate of dysphagia was 
significantly decreased in patients with HNC treated with amifostine during RT (30). 
A reduction in xerostomia may theoretically ameliorate dysphagia by improving 
mastication and preparation of food boluses.  It would also help to propel the bolus 
through the pharynx without the need for supplementing every solid food bolus with a 
liquid.  A reduction of free radicals may also decrease mucosal toxicity, which in turn 
may reduce the chance of developing fibrosis and an associated long term dysphagia.  
 
Recent studies suggest that proactive swallowing therapy delivered early, during RT, 
may in fact prevent later problems (31-33).  Some other studies, however, 
demonstrated no long-term benefit of swallowing exercises on dysphagia (34).  A 
recent study by Carnaby-Mann et al (35) demonstrated a greater preservation of 
certain muscles during RT following active swallowing exercises (pharyngocise). 
Although there was no overall difference in clinical swallowing outcomes at 6 weeks 
post RT, the study found that muscle function, measured by T2 weighted MRI, 
deteriorated less in the exercise group as compared to the control group.  
 
While preliminary evidence suggests that proactive interventions may be efficacious, 
it may be difficult to convince patients to perform proactive swallowing exercises for 
a “potential future problem”, especially when they are going through a taxing therapy 
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for their cancer.  Predictive statistics for RT-induced dysphagia would be critical in 
helping clinicians and patients decide an appropriate course of therapy. 
 
 
Assessment of Dysphagia 
There are various methods for assessing swallowing function including clinical and 
instrumental methods.  Clinical evaluation involves identification of swallowing 
abnormalities through evaluation of swallow function, collaboration with dieticians, 
patient education, potential swallow therapy, and identification of patients at a high 
risk of aspiration (8).  Table 2 lists some triggers for evaluation of dysphagia. 
 
Table 2: Triggers for evaluation of dysphagia8 
 
• Incapacity to control saliva, food, or liquids in the oral cavity 
• Food pocketing in cheek 
• Coughing or choking before, during, or after swallowing 
• Excessive chewing 
• Subjective complaint of difficulty swallowing 
• Subjective complaint of food “sticking” in throat 
• Unusual voice quality after swallowing 
• Weight loss 
 
A medical history, oral and oropharyngeal examination, and swallow trials comprise a 
comprehensive clinical swallowing examination.  A medical history includes 
complaints of swallowing by patients, avoidance of foods of specific consistencies, 
episodes of choking or coughing up food, poor nutrition, prior oral or oropharyngeal 
resection or CRT, presence of a feeding tube, and history of neurological issues. 
Patient perceptions of dysphagia are highly subjective and variable, an observation 
reported by a number of studies (36, 37).  An oral or oropharyngeal examination 
consists of oral cavity inspection, and evaluation of oral health (including dental 
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status), dryness, and motion, strength, and symmetry of the lips, jaws, tongue, and soft 
palate.  Additionally symptomatic dysphagia may be evaluated with a swallow test, 
which involves trials of different food and fluid consistencies of varying taste, 
temperature, and bolus sizes (38).   
 
Standardized questionnaires that measure patients’ QoL present an instrument to 
determine the impact of treatment.  Questionnaires such as the M.D. Anderson 
Dysphagia Inventory (MDADI) have been designed to specifically assess the impact 
of dysphagia on the QoL of patients with HNC (39). QoL describes outcome measures 
of psychosocial well-being and functional status using two measures; general and 
disease-specific (39).  Disease-specific measures evaluate specific patient populations 
or diagnostic groups and are more responsive to changes in status over time.  Finally, 
diet scales can be used to objectively measure what patients can eat.  An example is 
the Functional Oral Intake Scale (FOIS), a simple 7-point scale developed to rate the 
functional severity of dysphagia based on objective evaluations (40).  The 
Performance Status Scale for Head and Neck Cancer (PSS-HNC) also has an 11 point 
objective diet scale domain that can be used to measure changes in a patient’s ability 
to eat various consistencies over time.  Efficient, easy, and clinically realistic diet 
scales can improve dysphagia screening and allow for rapid referrals to speech 
language pathologists for dysphagia therapy. 
 
The most common instrumental method used to assess swallow function is the 
modified barium swallow (MBS), which uses videofluoroscopy to evaluate oral and 
pharyngeal function (24, 41).  A second comprehensive method is the Fiberoptic 
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Endoscopic Evaluation of Swallowing (FEES) that can be performed bedside and 
permits direct visualization of swallowing structures including the nasopharynx, 
hypopharynx, larynx, and vocal cords (8).  It also allows functional assessment 
including sensory deficits, movement of structures in view, handling of secretions, 
and ability to swallow food and liquid safely and effectively (8).  Videofluoroscopy is 
often considered to be the gold standard since it was established before FEES and is 
available at most major medical institutions.  However its use is limited due to high  
cost, lack of portability, and exposure to radiation.  Objective swallowing assessment 
with either FEES or videofluoroscopy should be used to evaluate swallowing function 
over time in clinical trials involving RT.  
 
The significance of objective swallowing function has been demonstrated by Agarwal 
et al (53) who looked at the patterns of objective swallowing dysfunction following 
CRT in patients with HNC (53).  Their study demonstrated that at 6mo post RT, 
patients presented with higher rates of “significant” residue (bolus left in the pharynx 
after swallowing), aspiration (bolus entering the airway), and need for postural 
changes (changing head or body positioning during the swallow to prevent aspiration), 
as compared to pre-RT (baseline) rates.  Using the same cohort, Agarwal et al found 
that patient-related factors including subjective dysphagia and tumor volume 
correlated with objective swallow function, even prior to RT (43).  Since subjective 
reports of dysphagia are influenced by many factors, swallowing assessment using 
objective instrumental exams are critical in evaluating outcomes in future studies 
involving RT. 
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Patient-reported and clinician-reported scoring systems such as Radiotherapy 
Oncology Group (RTOG) late radiation toxicity scoring, and the Common Toxicity 
for Adverse Events (CTCAE) are the most common methods employed in radiation 
oncology research to assess patient health during and following RT.  These scales 
however lack the specificity required to identify potentially detrimental swallowing 
dysfunction (42).  Given that a recent systematic review concluded that evidence for 
swallowing outcomes in HNC patients is limited (42), the aforementioned objective 
outcome measures such as diet, QoL, and results of instrumental swallow studies 
should be incorporated in all future clinical trials to more accurately establish 
treatment efficacy and long term outcomes. 
 
Prevalence of Dysphagia 
The reported prevalence of dysphagia following RT varies tremendously, from as low 
as 15% (44) to as high as 85% (45). This huge discrepancy suggests that the true 
prevalence and incidence is unknown.  There are numerous reasons for this.  First, 
there are a multitude of known factors that may affect prevalence of dysphagia, 
including dosage of radiation delivered, cancer stage, the addition of surgery, and the 
site of the cancer.  Other potential variables include age, body mass index (BMI), 
smoking/drinking history, and type of radiation used.   
 
The terms incidence and prevalence should be used uniformly, but sometimes this is 
not the situation.  An “incidence” study should identify the population to be studied 
and then identify all patients who develop the problem of interest in that population 
over a specified period of time (such as over one year).  A “prevalence” study should 
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follow the same patients over time and report the frequency of the problem at different 
time points (such as at 12 months post RT).  Some studies have reported a high 
prevalence or incidence of dysphagia, but on closer inspection, it is revealed that they 
have “selected” patients from that population that are at higher risk of having 
dysphagia; for example only looking at patients who complained of a swallowing 
problem (9).  Other studies that have reported incidence of dysphagia have not kept 
the post-RT time constant; their figures have represented the frequency of dysphagia 
in patients who were anywhere from 3 months to 10 years post RT (20, 26, 37, 46). 
This is extremely important since the literature suggests that the severity of dysphagia 
may vary over time.  
 
One major incidence study of dysphagia (47) looked at over 8000 patients from the 
Surveillance Epidemiology and End Results (SEER) registry and Medicare database 
over a 7-year period.  Its objectives included determination of the overall and site-
specific dysphagia and to calculate treatment-specific incidence rates.  It reported the 
incidence of dysphagia to be 40% within 3 years of diagnosis of HNC.  Furthermore 
patients who underwent CRT had more than 2.5 times greater odds of dysphagia 
compared to those who underwent solely surgery.  Dysphagia in this study was 
identified using the ICD-9 code.  This study represents our most systematic estimate 
of ‘incidence’ to date. 
 
A noteworthy potential source of variance is the definition or indicator of dysphagia.  
Different sources have used definitions including “patient report or complaint of a 
swallowing problem”, “diet restriction”, “feeding tube in place”, or findings from an 
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instrumental swallow study.  These different indicators of dysphagia have yielded 
widely different incidence figures.  Even using the same indicator, results have shown 
little agreement.  For example, Agarwal et al (43) used diet restrictions as an indicator 
and reported 73.5% of their patients were on a semi solid or liquid diet at 6 months 
post- RT.  Another study by Langendijk et al (44), using the RTOG /EORTC scale 
(48) reported that at 6 months post treatment, 23.1% of the patients were on a semi-
solid or worse diet.  Reasons for the disparities are not known.  Perhaps the lower 
prevalence figure in the latter study may have been due to the fact that they pre-
selected patients by excluding those with moderate dysphagia at baseline (pre-
treatment). 
 
Wilson et al (49) used the MD Anderson Dysphagia Index (patient-perceived Quality 
of Life (QOL) scale) (48) as an indicator of dysphagia.  At 3 months post-RT, 85% of 
all their patients reported a swallowing problem, with patients receiving 
chemoradiation reporting the worst QOL scores.  Over the course of the first year 
after treatment, there was no significant variation in QOL scores.  QOL is a variable 
that may be vulnerable to many factors; one study suggested that patient-reported 
QOL varied tremendously by culture and time since the treatment for HNC (50).  
Studies that have used “presence of a feeding tube” as an indicator of dysphagia have 
reported a declining prevalence over the first year, but tremendous variation between 
studies; 4-55% (11, 51, 52).  Early variance (3 months post-RT) may be related to the 
policy at some institutions of placing feeding tubes prophylactically in all patients 
prior to CRT.  However, from 6 months post-RT or later, it is likely that “feeding 
tube” would be a mark of a “severe” dysphagia. 
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Very few studies have reported incidence or prevalence of dysphagia from clinical or 
instrumental swallowing studies, probably because these exams are rarely given to all 
patients, requiring clinical expertise, adequate SLP staffing, and easy access to 
equipment.  Both Logemann (37) and Agarwal et al (53) have described the 
swallowing patterns using fluoroscopy procedures in relatively small groups of 
patients after RT, but neither specified how patients were selected, so accurate 
prevalence or incidence cannot be derived.  A large cohort from four institutions was 
reported by Pauloski et al (46).  Their results may reflect the “typical” patient 
although selection was not specified.  However, about half the patients had “no 
complaints” of swallowing so they obviously did not select for patients with 
dysphagia.  Their results indicated that patients with complaints did manifest worse 
swallowing as measured by MBS than patients without complaints, especially for 
findings of aspiration and pharyngeal residue, suggesting that patient complaint may 
be a reliable marker for a problem.  On the other hand, Kendall et al (54), in a smaller 
study, reported on fluoroscopy findings from 20 patients who had not pursued 
treatment for a swallowing problem.  They found that all of the patients had 
“abnormal swallowing” compared to their normal controls.  Therefore it appears that 
this marker of dysphagia may vary between patients and that some patients may even 
“underreport” their problem.   
 
Time since RT is also an important factor for understanding prevalence or incidence 
of dysphagia.  In the acute stages of RT, including the weeks during the RT and the 
first 3 months after RT, patients may experience inflammation, pain, xerostomia, and 
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alterations in taste which all affect their ability to swallow.  Consequently most 
patients will complain of some problem eating or swallowing up to 3 months post RT.  
As the acute effects subside, the trend of the problem is difficult to predict. Some 
patients recover while others continue to suffer from dysphagia.  After the first year, 
swallowing function may stabilize or it may worsen.  Some studies describe 
improvement over time (55, 32) while others report a worsening problem (56, 57) and 
still others have found no overall significant change over time (37, 49). 
 
In summary, it appears that true incidence and prevalence of dysphagia are elusive 
and depend on numerous factors.  Instrumental measurement appears to be the most 
sensitive marker and tube feeding is likely a marker for a severe dysphagia if present 
in the long term.  Patient reports and diet restrictions likely fall somewhere between 
the other two markers.  In the study mentioned above, Pauloski (46) found that patient 
complaint and diet restrictions were highly correlated.  However a study comparing 
observer/clinicians vs. patient-reported symptoms found that observers tended to 
under-report the severity of symptoms compared to patients’ self-report (58).  Hence 
the two sources of report should not be deemed to be equivalent.  
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Aims 
The value of determining the true incidence and prevalence of dysphagia is 
remarkable.  Health care providers have little information regarding the probability of 
dysphagia development in when counseling their patients before treatment for their 
cancer.  This also makes prescribing appropriate behavioral treatment for dysphagia 
difficult.   It may be relatively easy to motivate a patient to perform intensive, daily 
exercises for an existing dysphagia, but it is nearly impossible to motivate a patient 
who is about to undergo RT to engage in daily exercises for a “possible swallowing 
problem that may affect them in the next year” or later.   
 
In response to this gap in knowledge, a retrospective cohort study was carried out to 
determine the prevalence of, trends in, and risk factors for, dysphagia following 
completion of radiation therapy at 3, 6, 9, and 12 months in patients diagnosed with 
head and neck cancer at Boston Medical Center over a 7-year period. 
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METHODS 
A retrospective cohort study was conducted that involved a chart review of the 
medical records of all patients who completed radiation therapy for head and neck 
cancer from January 1, 2003 to December 31, 2009 at Boston University Medical 
Center.  Approval was obtained from the Boston University Medical Center 
Intuitional Review Board prior to collecting and analyzing patient data.  An initial 
search revealed 2104 patient records.  Patients were excluded if they did not have a 
malignancy, their treatment fell outside the eligibility window, if their cancer was not 
in an eligible location (esophagus, thyroid, base of skull, other), if the patient declined 
treatment, if the patient received RT at a different hospital, or if there was incomplete 
information about their HNC therapy.  This conferred a final list of 260 patients.  
 
Next, patients were excluded from the list of 260 patients if they did not have 
adequate records at 3, 6, 9, or 12 months post RT, had previous RT for HNC, received 
RT but were deceased at 3 months post-RT, did not receive a full dose of RT (less 
than 50Gy), received only surgery and/or chemotherapy, if they received RT at 
another hospital, or had a neurologic disorder or history of one.  Following these 
exclusions, 113 eligible patients were left who had comprehensive treatment and 
follow up data at 3, 6, 9 or 12 months post RT.  Figure 1 illustrates the exclusion of 
patients. 
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 Figure 1:  CONSORT flow diagram of patients excluded 
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Patient declined treatment 
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Re-assessed for eligibility 
(n=260) 
Excluded (n=147) 
 
Inadequate records at 3, 6, 9, or 12 months 
post RT. 
Prior RT for HNC 
Received RT but deceased at 3 mo post RT 
Incomplete course/dose of RT 
Received only surgery &/or chemotherapy 
Had a neurologic disorder or history of one 
  
Analyzed 
(n=113) 
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For each patient, age, gender, cancer stage, cancer site, treatment course (solely RT or 
with chemotherapy and/or surgery), radiation type, time of surgery in relation to RT, 
extent of surgery, previous treatment for HNC, cancer status at 3, 6, 9, and 12 months 
post RT, BMI at start of RT, HPV status (unavailable until 2009), tobacco use, alcohol 
consumption, clinic visits with SLP and PEG placement were all noted as predictor 
variables. 
 
Outcome variables of interest included feeding tube status (regardless of use), diet 
status (Table 3), subjective swallow status, and percent weight loss from end of RT.  
All outcome data were acquired at 3, 6, 9, and 12 months post completion of RT (+/- 1 
month to account for scheduling differences).  If there were multiple reports of the 
same category (i.e. subjective diet status) within the time window, the most severe 
(worst) outcome was used. 
 
Documentation of subjective swallow status data was only included if concrete 
statements on swallow status were made.  Patient or clinician report of a problem with 
swallowing was categorized as “none”, “mild/moderate”, or “severe”.  Phrases such as 
“trouble swallowing” and “some dysphagia” were considered to be in the 
mild/moderate category.  Severe dysphagia was categorized by “cannot swallow” or 
“significant problems eating”.  Normal swallowing was categorized as “no trouble 
swallowing” or “no dysphagia”.  Phrases such as “patient feels fine” or “doing well” 
were not specific enough to appropriately determine normal swallow status, and were 
categorized as “unknown” subjective swallow status. 
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Severe Moderate  Any  Mild 
Diet status determination and documentation was treated with the same methodology 
as subjective swallow status.  It was defined by what the patient could eat (Table 3). A 
normal diet would be categorized by “eating full diet” or “can eat everything”.  
Reports of “eating well”, “tolerating diet well” or “strong appetite” were not specific 
enough to appropriately determine actual diet status, and therefore were categorized as 
unknown diet status.  
 
 
 
 
Prevalence was studied according to three indicators or markers of dysphagia: current 
diet, report of swallowing difficulty, or use of a feeding tube.  Prevalence was defined 
as the number of patients with dysphagia at 3, 6, 9, and 12 months, with each patient 
able to be counted multiple times.  We also informally looked at when persons first 
developed dysphagia. 
 
Statistical analyses were performed using SAS software, version 9.2 (SAS Institute 
Inc, Cary, NC, USA). Categorical variables were compared across risk groups using 
Fischer’s exact test. Analyses of Variance (ANOVA) F-tests and T-tests were used to 
compare continuous variables. 
 
Table 3: Diet Status Grading 
Grade       Diet Status 
1            No oral intake 
    2            PEG use with some oral intake 
    3            Total oral intake but with limited consistencies 
    4            Total oral intake with no special preparation 
                  but some food avoidance or liquid wash 
    5            Total oral intake with no restrictions other 
                   than edentulous 
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Generalized Estimating Equations (GEE), a quasi-likelihood approach to modeling 
clustered or repeated data, was introduced by Zeger and Liang (1986).  The cluster in 
our study was the individual and the repeated measure represented the multiple 
measures over time.  The covariates in the model could be both categorical and 
continuous.  The GEE modeling approach is able to accommodate various dependent 
variables including Gaussian, gamma (skewed distributions), binomial, or count. 
Using this approach, the user needs to make assumptions about the link function and 
the relationship between the first two moments.  A logit link was used in modeling 
probability of dysphagia.  The effects included in the model were risk factors, time, 
and the interaction between them.  The same model was then used to test differences, 
in terms of association between risk factors and outcome, at each time point. 
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RESULTS 
 
Population Demographics 
 
113 patients were identified for this study, of which 31% (n=35) were female and 
69% (n=78) were male.  Average age was 58.6 years old (35 to 88).  The most 
common cancer sites were oropharynx and nasopharynx (38.9%) as well as 
hypopharynx and larynx (31%).  Fewer subjects had cancer of the oral cavity (18%) 
or “other” site (14.2%).  The majority of the patients (60.2%) had Stage 4 cancer with 
the second most common stage being Stage 3 (22.2%).  71.7% of the cohort had 
chemotherapy (CT) in addition to RT, and about half the patients had some degree of 
surgery.  The extent of surgery was most frequently limited to less than 50% of the 
oropharynx, hypopharynx, or larynx.  IMRT was used in the majority of patients 
(74.5%) as opposed to conventional 3D RT (25.5%).  Table 4 summarizes the 
demographics of this group.  Some variables were not included in the final output if  
there was negligible or no recorded data for that variable. 
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Table 4: Patient Demographics 
 
Characteristic  Overall (N=113)  
Gender  
     Female 35 (31%) 
     Male 78 (69%) 
Age  
     Mean ± SD 58.558±10.212 
     Median and Range 59 (35-88) 
BMI  
     Mean ± SD 26.88±7.011 
     Median and Range 26.2 (14.9-53.9) 
Tobacco Use  
     Never 18 (16.2%) 
     Prior only 53 (47.7%) 
     Prior and during 40 (36%) 
Alcohol Use  
     Never 59 (53.2%) 
     Prior only 32 (28.8%) 
     Prior and during 20 (18%) 
Cancer Site  
     OC 18 (15.9%) 
     NP/OP 44 (38.9%) 
     HP/Larynx 35 (31%) 
     Other 16 (14.2%) 
Cancer Stage  
     1 12 (11.1%) 
     2 7 (6.5%) 
     3 24 (22.2%) 
     4 65 (60.2%) 
Chemotherapy  
     Yes 81 (71.7%) 
     No 32 (28.3%) 
Type of Radiotherapy  
     IMRT 82 (74.5%) 
     Conventional 3D RT 28 (25.5%) 
Surgery  
     Yes 56 (49.6%) 
     No 57 (50.4%) 
When Was Surgery Done  
     Before RT 43 (38.1%) 
     After RT 5 (4.4%) 
     No surgery 57 (50.4%) 
     Both before and after RT 8 (7.1%) 
Extent of Surgery  
     None or Biopsy 57 (50.4%) 
     Neck Dissection or Tonsillectomy 12 (10.6%) 
     Resected<50% of OC, NP, OP, HP or Larynx 29 (25.7%) 
     Resected>50% of OC, NP, OP, HP or Larynx 15 (13.3%) 
PEG Placed  
     Never 56 (50%) 
     Before or during RT 47 (42%) 
     After RT completion 9 (8%) 
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Prevalence of Dysphagia 
 
The prevalence of dysphagia at 3, 6, 9, and 12 months was determined by the first set 
of analyses according to three indicators: any diet restriction (a diet score of 1-4 
depicted in Table 1), feeding tube in place, and report of any swallowing problem 
(mild, moderate, or severe) by the patient/clinician.  Prevalence varied by type of 
marker for dysphagia and ranged from 27% at 12 months post RT, indicated by use of 
a feeding tube to 74% at 6 months post RT, indicated by any diet restriction Table 5 
and Figure 2 depict these results.  Linear trends were not significant for the three 
measures.  
 
Table 5: Prevalence of Dysphagia over Time and by Indicator of Dysphagia 
 
Time 
Post 
RT 
Any Diet Restriction 
 
Report of Swallowing 
Problem 
Feeding Tube 
Probability of 
Dysphagia CI 
Probability of 
Dysphagia CI 
Probability of 
Dysphagia CI 
3mo 0.685 0.584-0.771 0.485 0.385-0.586 0.345 0.262-0.438 
6mo 0.740 0.647-0.815 0.632 0.536-0.719 0.329 0.248-0.421 
9mo 0.681 0.580-0.768 0.500 0.396-0.603 0.339 0.255-0.436 
12mo 0.671 0.565-0.762 0.464 0.355-0.577 0.269 0.191-0.364 
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Figure 2: Prevalence of Dysphagia over Time and by Indicator of Dysphagia 
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In general, the presence of a feeding tube yielded the lowest estimates of dysphagia. 
The highest estimates of dysphagia were indicated by the presence of any diet 
restriction (defined as diet grades 1-4 in Table 3).  Subjective reports of a swallow 
problem fell between these two estimates.  The lowest estimate was 27% at 12 months 
as indicated by the presence of a feeding tube while the highest estimate was 74% at 6 
months as indicated by any diet restriction.  Over time, presence of a feeding tube 
remained fairly constant then declined between 9 and 12 months post RT.  The 
restrictions in diet and report of swallowing problem peaked at 6 months post RT then 
declined. 
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Diet status was analyzed in three different ways; (a) Severe dysphagia (diet grade 1-2 
which indicated people were using their PEG for some or all of their nutritional 
intake), (b) Moderate/Severe (diet grades 1-3 which indicate people were either using 
their PEG or having to significantly alter their diet), (c) any diet restriction (diet 
grades 1-4).  Prevalence of dysphagia for 3 of these defined groups is delineated in 
Figure 3.  The only indicator that showed a significant negative trend was moderate to 
severe diet restriction  (p = 0.005). 
 
Figure 3: Prevalence of Dysphagia over Time by Diet Restriction Definition 
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The probability of having any diet restriction was more than 67% at all time points 
whereas the probability of having a severe diet restriction was less than 26% at all 
time points.   
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Severe dysphagia as defined by presence of a PEG ranged from approximately 27% 
to 34.5% (see Figure 2), but this differed from the results of severe dysphagia as 
defined by the actual use of a PEG (as defined by Diet levels 1+2 in Table 3).  This 
discrepancy is shown in Figure 4 and suggests that presence of a PEG may not be a 
particularly accurate indicator of severe dysphagia.  
 
Figure 4: Prevalence of Severe Dysphagia over Time – Presence of PEG vs. Use of 
PEG. 
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Subjective patient / clinician report of a swallowing problem was analyzed as two 
groups: any swallowing problem vs. report of a severe swallowing problem.  At 6 
months, 63% of patients reported having any swallowing problem but only 18% 
reported a severe swallowing problem (Figure 5). 
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Figure 5: Prevalence of Dysphagia over Time by Subjective Patient / Clinician 
Assessment 
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Since the three markers did not correlate highly with dysphagia, a decision was made 
to identify the most clinically meaningful marker.  Presence of a feeding tube was 
eliminated first since it only represented a rough estimate of “severe dysphagia” and it 
did not seem to correlate with actual use of the feeding tube (ie what the patients were 
actually able to eat).  Subjective patient / clinician report of dysphagia was eliminated 
next as it might have been unreliable, at least in this study which depended on written 
entries into the medical record.  Inspection of our records indicated that reliability was 
highly influenced by the skill and care taken by the health care provider who needed 
to ask the right questions and report it accurately.  Hence inter-provider reliability was 
poor and we did not have a gold standard for reliability.  Reliability was also 
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influenced by how honest or forward the patient was about reporting this problem; 
clinicians are well aware that some patients do not complain to their cancer doctor 
even if they have a significant problem eating while others complain fervently about 
the slightest thing. Thus, the most clinically meaningful marker of dysphagia was 
deemed to be diet level, which is a more objective reflection of a person’s true 
dysphagia status. 
 
Since diet restriction had been categorized in several different ways (Figure 3), it was 
decided that the moderate / severe diet restriction group was the most meaningful 
(Diet levels 1-3) because it seemed to clinically impact the patient the most.   This 
categorization did not include patients who altered their diet solely because they were 
edentulous, only needed to use a liquid wash, or had such mild problems that they 
would be unlikely to seek out therapy.  Accordingly, the moderate/severe category 
included all patients who had to alter their diet to eliminate whole categories of food 
items, and their dysphagia was severe enough to impact their lives.  This degree of 
diet restriction was considered meaningful not only clinically, but also personally for 
the patient.  The remaining analyses were performed using this most “clinically 
meaningful” indicator of dysphagia. 
 
Altogether, this most “clinically meaningful” indicator of dysphagia showed that the 
prevalence or probability of dysphagia to be 49% at 3 months, 56% at 6 months, 45% 
at 9 months, and 31% at 12 months.   
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Significant Predictors of Dysphagia 
The second set of analyses attempted to determine the most accurate predictors of 
dysphagia, defined by moderate / severe diet restriction.  Several variables were 
analyzed including cancer site, cancer stage, age, gender, BMI, surgery, CRT, 
prophylactic PEG placement, alcohol consumption, and tobacco use.  Six and twelve 
months were chosen as the two most important time points post RT, beyond the acute 
toxicity stage and more likely representing a chronic swallowing problem that would 
be meaningful and concerning to patients and clinicians alike.  Table 6 summarizes 
results of the univariate analyses showing the association of moderate-severe 
dysphagia at 6 months with the predictor variables and Table 7 shows these 
associations at 12 months.  
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Table 6: Univariate Results:  Association of Independent Variables with Moderate-
Severe Dysphagia at 6 months 
 
Characteristic Overall     (N=88) 
Dysphagia 
(N=55) 
No Dysphagia 
(N=33) p-value 
Age, N (%)     
     Less than 60 49 (55.7%) 34 (69.4%) 15 (30.6%) 0.184 
     60 and older 39 (44.3%) 21 (53.8%) 18 (46.2%)  
Gender, N (%)     
Male 60 (68.2%) 42 (70%) 18 (30%) 0.057 
     Female 28 (31.8%) 13 (46.4%) 15 (53.6%)  
BMI, N (%)     
     Less than 25 44 (50%) 31 (70.5%) 13 (29.5%) 0.186 
     25 and higher 44 (50%) 24 (54.5%) 20 (45.5%)  
Excessive Tobacco Use, N 
(%) 
    
     Yes 36 (41.9%) 25 (69.4%) 11 (30.6%) 0.263 
     No 50 (58.1%) 28 (56%) 22 (44%)  
Excessive Alcohol Use, N (%)     
Yes 17 (19.8%) 14 (82.4%) 3 (17.6%) 0.057 
     No 69 (80.2%) 39 (56.5%) 30 (43.5%)  
CRT, N (%)     
     Yes 72 (81.8%) 47 (65.3%) 25 (34.7%) 0.268 
     No 16 (18.2%) 8 (50%) 8 (50%)  
Surgery, N (%)     
     Yes 40 (45.5%) 24 (60%) 16 (40%) 0.666 
     No 48 (54.5%) 31 (64.6%) 17 (35.4%)  
Cancer Site, N (%)     
     OC 15 (17%) 13 (86.7%) 2 (13.3%) 0.160 
     NP/OP 36 (40.9%) 22 (61.1%) 14 (38.9%)  
     HP/Larynx 27 (30.7%) 15 (55.6%) 12 (44.4%)  
     Other 10 (11.4%) 5 (50%) 5 (50%)  
Cancer Stage, N (%)     
     Stage 1&2 11 (13.3%) 6 (54.5%) 5 (45.5%) 0.797 
     Stage 3 18 (21.7%) 11 (61.1%) 7 (38.9%)  
     Stage 4 54 (65.1%) 35 (64.8%) 19 (35.2%)  
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Table 7: Univariate Analyses: Association of Independent variables with Moderate-
Severe Dysphagia at 12 months 
 
Characteristic Overall     (N=66) 
Dysphagia 
(N=23) 
No Dysphagia 
(N=43) p-value 
Age, N (%)     
     Less than 60 36 (54.5%) 12 (33.3%) 24 (66.7%) 0.801 
     60 and older 30 (45.5%) 11 (36.7%) 19 (63.3%)  
Gender, N (%)     
     Male 45 (68.2%) 16 (35.6%) 29 (64.4%) 0.999 
     Female 21 (31.8%) 7 (33.3%) 14 (66.7%)  
BMI, N (%)     
     Less than 25 27 (40.9%) 12 (44.4%) 15 (55.6%) 0.198 
     25 and higher 39 (59.1%) 11 (28.2%) 28 (71.8%)  
Excessive Tobacco Use, N (%)     
     Yes 28 (42.4%) 10 (35.7%) 18 (64.3%) 0.999 
     No 38 (57.6%) 13 (34.2%) 25 (65.8%)  
Excessive Alcohol Use, N (%)     
     Yes 12 (18.2%) 6 (50%) 6 (50%) 0.316 
     No 54 (81.8%) 17 (31.5%) 37 (68.5%)  
CRT, N (%)     
     Yes 52 (78.8%) 20 (38.5%) 32 (61.5%) 0.346 
     No 14 (21.2%) 3 (21.4%) 11 (78.6%)  
Surgery, N (%)     
     Yes 32 (48.5%) 9 (28.1%) 23 (71.9%) 0.309 
     No 34 (51.5%) 14 (41.2%) 20 (58.8%)  
Cancer Site, N (%)     
     OC 10 (15.2%) 4 (40%) 6 (60%) 0.100 
     NP/OP 26 (39.4%) 12 (46.2%) 14 (53.8%)  
     HP/Larynx 22 (33.3%) 7 (31.8%) 15 (68.2%)  
     Other 8 (12.1%) 0 (0%) 8 (100%)  
Cancer Stage, N (%)     
     Stage 1&2 9 (14.3%) 2 (22.2%) 7 (77.8%) 0.735 
     Stage 3 12 (19%) 5 (41.7%) 7 (58.3%)  
     Stage 4 42 (66.7%) 16 (38.1%) 26 (61.9%)  
 
 
As can be seen in Tables 6 and 7, the only predictor variables that were (marginally) 
significantly associated with moderate-severe dysphagia at 6 months were:  male 
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gender (p = 0.057) and alcohol history (p = 0.057).  However these were no longer 
significant at 12 months and no other variables emerged at that time point. 
 
Multivariate analyses were performed after accounting for correlations among the 
independent factors.  The variables analyzed were age, gender, BMI, tobacco use, 
alcohol consumption, CRT, surgery, cancer site, and cancer stage.  These analyses are 
shown in Table 8 and 9.  From all the assumed predictors, only cancer site (oral vs. 
hypopharyngeal or laryngeal cancer) was a significant predictor at 6 months post RT– 
with oral cancer site having worse swallowing outcomes.  At 12 months post RT, 
again, no significant predictors of moderate to severe dysphagia were identified in our 
cohort. 
 
 
 
Table 8: Multivariate Analyses:  Predictors of Moderate-Severe Diet Restrictions at 6 
months (c=0.751) 
 
 
Adj. Odds 
Ratio 
Lower 
Confidence 
Limit 
Upper 
Confidence 
Limit p value 
Men vs. Women 1.7922 0.4776 6.7254 0.3872 
Age <60 vs. >60 1.4084 0.4065 4.8800 0.5891 
BMI <25 vs. >25 2.2471 0.7441 6.7863 0.1511 
Tobacco Use 1.0266 0.2453 4.2968 0.9714 
Alcohol Use 2.3243 0.3786 14.2676 0.3623 
CRT 3.4368 0.4865 24.2775 0.2158 
Surgery 0.5735 0.1718 1.9151 0.3661 
Cancer Site: OC vs. HP/Larynx 17.2956 1.1635 257.1024 0.0385 
Cancer Site: NP/OP vs. HP/Larynx 1.1891 0.3671 3.8521 0.7727 
Cancer Stage: 1&2 vs. 4 1.5880 0.1836 13.7364 0.6744 
Cancer Stage: 3 vs. 4 0.5942 0.1586 2.2258 0.4398 
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Table 9: Dysphagia: Multivariate Analyses:  Predictors of Moderate Diet Restrictions 
at 12 months (c=0.729) 
 
 
Adj. 
Odds 
Ratio 
Lower 
Confidence 
Limit 
Upper 
Confidence 
Limit p value 
Men vs. Women 1.4912 0.3286 6.7661 0.6046 
Age <60 vs. >60 0.7865 0.2289 2.7028 0.7029 
BMI <25 vs. >25 1.6236 0.4254 6.1970 0.4782 
Tobacco Use 1.1471 0.2206 5.9644 0.8704 
Alcohol Use 2.8578 0.3726 21.9173 0.3124 
CRT 2.2108 0.1620 30.1798 0.5519 
Surgery 0.7110 0.1700 2.9733 0.6403 
Cancer Site: OC vs. HP/Larynx 0.4906 0.0575 4.1836 0.5149 
Cancer Site: NP/OP vs. HP/Larynx 2.3849 0.5141 11.0627 0.2669 
Cancer Stage: 1&2 vs. 4 0.5749 0.0229 14.4277 0.7364 
Cancer Stage: 3 vs. 4 2.5498 0.3714 17.5045 0.341 
 
 
 
Trends in Dysphagia  
A third analysis was performed to determine trends in dysphagia over the first year.  It 
was determined that about 38% of our cohort developed, for the first time, a moderate 
to severe dysphagia by 3 months post RT.  An additional 17-18% developed a newly 
diagnosed moderate to severe dysphagia by 6 months post RT.  Only two patients 
developed a moderate to severe dysphagia after 6 months.  This suggests that patients 
who develop a moderate to severe dysphagia tend to do so within the first 6 months 
following completion of RT.  However, this must be interpreted with caution since 
many patients were missing data at 9 and 12 months post RT.  As a result there may 
have been additional patients who developed moderate to severe dysphagia at some 
time after 6 months post RT.  Table 10 summarizes the first onset of dysphagia over 
the first year.  
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  Table 10: Trends in Dysphagia Development by Diet Restrictions 
 
Outcome Month Cumulative Quarterly 
Percent of 
Cohort 
Any diet restrictions 
3 61 61 0.540 
6 80 19 0.708 
9 85 5 0.752 
12 86 1 0.761 
Moderate/Severe diet restrictions 
3 43 43 0.381 
6 63 20 0.558 
9 65 2 0.575 
12 65 0 0.575 
Severe diet restrictions 
3 19 19 0.168 
6 30 11 0.265 
9 32 2 0.283 
12 32 0 0.283 
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DISCUSSION 
The purpose of this study was to determine the prevalence of dysphagia over the year 
following RT, any potential predictors of dysphagia, and any trends of dysphagia 
development in our retrospective study at Boston Medical Center.   
 
The analysis of our prevalence data was conducted in various ways, using indicators 
of dysphagia and by severity of dysphagia within each indicator.  The data were 
analyzed at four time points- 3, 6, 9, and 12 months post RT. A decision was made to 
use “moderate to severe” diet restriction as the measure of a moderate to severe 
dysphagia in order to bring some order to a data set that depicted widely different 
prevalence rates depending on indicator definition.  This level of diet restriction was 
thought to be a substantial indicator that would impair quality of life and that would 
likely motivate a patient to seek treatment. With moderate or severe diet restriction as 
the indicator of dysphagia, the prevalence of dysphagia in the year following RT was 
49% at 3 months, 56% at 6 months, 45% at 9 months, and 31% at 12 months.  These 
results fell approximately mid-way between 2 previously cited studies that used diet 
as an indicator of dysphagia, which reported a prevalence at 6 months of 23.1% (42) 
and 73.5%, (59).  The overall proportion of patients who developed dysphagia over 
the first year by moderate/severe diet marker, 56%, was higher than the 39.8% 
incidence reported to occur over the first three years using SEER and Medicare 
coding data (47).  Our study calls into question whether coding/billing data 
underestimates the true incidence, as suggested by authors themselves. Second, the 
data collected for the study was in the 1990s, with a noted rise in incidence over the 
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decade from 33% to 44%.  Our data were collected in the 2000s, which may reflect 
the a continuing trend since cancer treatments become more aggressive.  
 
These results suggest that about fifty percent of patients who undergo RT may be 
expected to develop a significant swallowing dysfunction in the first year following 
RT.  This is extremely useful data for a health care provider to present to a patient 
after diagnosis of HNC and should complement counseling provided to them at the 
time of molding a treatment plan. 
 
Trends in dysphagia were also analyzed with moderate to severe diet restriction as the 
most “clinically meaningful” indicator of moderate/severe dysphagia.  Interestingly all 
but two of the patients who developed moderate/severe dysphagia did so within the 
first 6 months of completion of RT.  A similar observation was made when looking at 
“any” and “severe” diet outcomes.  Due to missing data in the 9 and 12 month 
periods, analysis of the number of patients who showed a reversal in this pattern 
(those who developed dysphagia early on but recovered normal swallowing function 
during the first year after RT) was not conducted. 
 
Analysis of subjective patient report and clinician report of swallowing problems 
revealed that at 6 months following RT completion, of the 63% of patients who 
reported having any swallowing impairment only 18% reported a severe swallowing 
issue (Figure 5).  This is about 10% lower for both incidences than seen when using 
any and severe diet restriction as indicators, endorsing the assertion that patients tend 
to underreport their swallowing problems.  
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In patients with a severe dysphagia as defined as presence of feeding tube, prevalence 
of its use decreased only slightly over the first year but not as much as one would 
predict.  Perhaps some patients who had feeding tubes placed prophylactically had 
them removed while others developed a worsening dysphagia eventually necessitating 
the insertion of a feeding tube, perhaps for the first time, during the year after 
completion of RT.   
 
The two other markers for dysphagia (“any” diet restriction and any patient/clinician 
report of a swallowing problem) showed a worsening dysphagia at 6 months post RT 
but no significant negative linear trend from 3 to 12 months post RT.  The prevalence 
of dysphagia did not change substantially over the first year overall.  This agrees with 
Wilson et al (49) who used QOL scores as their indicator of dysphagia and suggested 
that the problem seen at 3 months is likely to continue over the first 12 months.  There 
are no studies that have followed patients beyond one year for prevalence statistics, 
however clinicians are cognizant of the fact that some patients continue to have 
swallowing abnormalities for many years.  Surprisingly some patients get worse, 
sometimes after several years of reportedly doing “ok”.  Evidently the long-term 
course of dysphagia after RT needs to be better understood.  
 
Awareness that the odds of developing dysphagia are approximately 50% may be a 
motivating factor for some patients to begin exercises.  Unfortunately our data did not 
identify any variables that could help predict who is at greater risk of developing such 
a long term dysphagia.  This study identified only oral malignancy as a significant risk 
factor at 6 months post RT.  As a result, it may be difficult for clinicians to motivate 
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their patients to undergo intensive, daily exercises for an issue that “might appear at 
some point in the next year” or later.  
 
Our study left some critical questions unanswered.  Who and why do some patients 
develop a dysphagia while others remained untouched?  Attempts to identify 
significant predictors of dysphagia in our cohort were surprising.  BMI, age, cancer 
stage, and smoking history were not found to be significantly associated with 
dysphagia, even though the literature suggested otherwise (60-62).  Only oral cavity 
as cancer site was associated with moderate/severe dysphagia in our cohort of 
patients.  Interestingly, while 75% of our cohort received IMRT, our prevalence 
figures are not much different from studies that did not use IMRT or only had a 
minority of patients that received IMRT therapy (23, 32, 34).   
 
The outcome may have been altered by one final variable, which is delivery of 
swallowing therapy.  Few of the patients received therapy for a dysphagia in this 
study so it could not be factored into the results.  None of the above cited incidence or 
prevalence studies included this as a factor, either.   
 
There have been several published small-scale clinical trials to determine the efficacy 
of exercise therapy to date, but with mixed results (34, 44, 55, 63-65).  A few studies 
suggest that delivery of early swallowing therapy during RT may help prevent later 
swallowing problems (34, 35).  With the results of the current study showing a 
prevalence of 50%, physicians may be encouraged to enroll patients into early therapy 
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i.e., during or end of RT.  However the real effect of intervention is still to be 
determined. 
 
 
Limitations 
Limitations of this study were a retrospective research design, relatively small sample 
size, no instrumental swallowing studies, no quality of life scale, lack of standardized 
scales for identifying diet or patient report, and single-center study.  Complaints of 
swallowing were evaluated using subjective accounts rather than objective 
instrumental measurements hence the degree of correlation between subjective reports 
by patients and objective measurements could not be established.  Additionally, the 
retrospective design of the study resulted in a few potentially significant clinical 
parameters to be excluded from collection.  For example, post RT alcohol and tobacco 
consumption was not collected.  Many subjects were excluded from the analysis due 
to lack of outcome data, hence our results may possibly be a slight over estimate of 
the actual global prevalence rate.  This is because it is possible that a greater 
proportion of patients with minimal or no swallowing troubles may not have had 
dysphagia status notes in the medical records since lack of dysphagia is not 
considered to be a documentation priority.  Furthermore we may have had a biased 
sample due to the exclusion of a huge proportion of the initial sample.  The chance of 
under documentation of no dysphagia may be higher than the lack of documentation 
of a mild or moderate dysphagia.  In spite of these limitations, it is, to our knowledge, 
the most systematic and comprehensive reflection of the true prevalence of dysphagia 
in HNC patients in the first year after RT available to the scientific and clinical 
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communities at this time.  Prospective studies that address the limitations of this one 
will add significant insight to this critical issue. 
 
 
Future Directions 
Future research efforts must be made to address several issues despite the limitations 
of our study.  A number of ideas for future projects arose from our study.  
Randomized clinical trials should be conducted to establish the clinical benefits of 
diagnosing dysphagia during and after RT.  This can be approached systematically if 
physicians and staff were to document dysphagia consistently using validated QoL 
and/or diet scales.  Institutions with sufficient SLP coverage could use standard 
protocols to evaluate patients with objective measurements including FEES, MBS, 
QoL, or diet scales.  These outcome measures should be collected at specific time 
points before, during and after therapy for head and neck cancer.  Future studies 
should evaluate the degree of correlation between subjective reports by patients and 
objective measures of swallowing in the setting of a prevalence or incidence study. 
 
Collecting accurate prevalence data to compare patients who did not undergo exercise 
therapy with those who did would be useful to future studies as well.  Future 
prospective studies could perform regular “screening” assessments to determine 
whether the assessments and subsequent therapeutic strategies have an impact on 
QoL.  Similarly, prospective studies could also determine whether regular 
instrumental swallow assessment during and/or after RT would alter the management 
of dysphagia.  This could potentially translate into modified standards of care during 
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or after radiation therapy to either prevent or treat any RT associated dysphagia.  A 
standardized practice could guide improved patient care and result in collection of 
comprehensive data for future research. 
 
 
Conclusion 
The results of our retrospective cohort study suggest that about half of patients who 
undergo RT may be expected to develop a major swallowing dysfunction within the 
first year of RT.  The majority of those who develop dysphagia are likely to do so 
within the first 6 months of completion of RT.  The only significant predictor of 
dysphagia was oral cavity as a cancer site.  Male gender and alcohol consumption at 6 
months post RT completion were marginally significant.  Altogether this is 
exceptionally valuable data for a health care provider to present to a patient following 
a diagnosis of HNC and should complement counseling provided to them at the time 
of fashioning a treatment plan. 
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